These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33437965)

  • 1. Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity.
    Boutagy NE; Feher A; Pfau D; Liu Z; Guerrera NM; Freeburg LA; Womack SJ; Hoenes AC; Zeiss C; Young LH; Spinale FG; Sinusas AJ
    JACC CardioOncol; 2020 Dec; 2(5):774-787. PubMed ID: 33437965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway.
    Dindaş F; Güngör H; Ekici M; Akokay P; Erhan F; Doğduş M; Yılmaz MB
    Anatol J Cardiol; 2021 Nov; 25(11):821-828. PubMed ID: 34734816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacubitril/valsartan attenuated myocardial inflammation, fibrosis, apoptosis and promoted autophagy in doxorubicin-induced cardiotoxicity mice via regulating the AMPKα-mTORC1 signaling pathway.
    Hu F; Yan S; Lin L; Qiu X; Lin X; Wang W
    Mol Cell Biochem; 2024 Sep; ():. PubMed ID: 39304614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/valsartan reduces endoplasmic reticulum stress in a rat model of doxorubicin-induced cardiotoxicity.
    Kim BS; Park IH; Lee AH; Kim HJ; Lim YH; Shin JH
    Arch Toxicol; 2022 Apr; 96(4):1065-1074. PubMed ID: 35152301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits.
    Torrado J; Cain C; Mauro AG; Romeo F; Ockaili R; Chau VQ; Nestler JA; Devarakonda T; Ghosh S; Das A; Salloum FN
    J Am Coll Cardiol; 2018 Nov; 72(19):2342-2356. PubMed ID: 30384891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
    Nordén ES; Bendiksen BA; Andresen H; Bergo KK; Espe EK; Hasic A; Hauge-Iversen IM; Veras I; Hussain RI; Sjaastad I; Christensen G; Cataliotti A
    ESC Heart Fail; 2021 Apr; 8(2):918-927. PubMed ID: 33497525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.
    Sharifi Kia D; Benza E; Bachman TN; Tushak C; Kim K; Simon MA
    J Am Heart Assoc; 2020 Jul; 9(13):e015708. PubMed ID: 32552157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
    Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
    Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
    Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
    Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect.
    Tashiro K; Kuwano T; Ideishi A; Morita H; Idemoto Y; Goto M; Suematsu Y; Miura SI
    Cardiol Res; 2020 Dec; 11(6):376-385. PubMed ID: 33224383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
    Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
    Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
    Myakala K; Jones BA; Wang XX; Levi M
    Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective Effects of Sacubitril/Valsartan on Cardiac Fibrosis and Function in Rats With Experimental Myocardial Infarction Involves Inhibition of Collagen Synthesis by Myocardial Fibroblasts Through Downregulating TGF-β1/Smads Pathway.
    Wu M; Guo Y; Wu Y; Xu K; Lin L
    Front Pharmacol; 2021; 12():696472. PubMed ID: 34135764
    [No Abstract]   [Full Text] [Related]  

  • 14. Protective effect of valsartan against doxorubicin-induced cardiotoxicity: Histopathology and metabolomics in vivo study.
    Alhazzani K; Alotaibi MR; Alotaibi FN; Aljerian K; As Sobeai HM; Alhoshani AR; Alanazi AZ; Alanazi WA; Alswayyed M
    J Biochem Mol Toxicol; 2021 Sep; 35(9):e22842. PubMed ID: 34273911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
    Habibi J; Aroor AR; Das NA; Manrique-Acevedo CM; Johnson MS; Hayden MR; Nistala R; Wiedmeyer C; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2019 Mar; 18(1):40. PubMed ID: 30909895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin-aldosterone system.
    Simko F; Stanko P; Repova K; Baka T; Krajcirovicova K; Aziriova S; Domenig O; Zorad S; Adamcova M; Paulis L
    Biomed Pharmacother; 2024 Apr; 173():116391. PubMed ID: 38461685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
    Li Q; Fang Y; Peng DW; Li LA; Deng CY; Yang H; Kuang SJ; Li QQ; Zhang MZ; Zeng P; Zhang QH; Liu Y; Deng H; Wei W; Xue YM; Wu SL; Rao F
    Eur J Pharmacol; 2023 Aug; 952():175754. PubMed ID: 37182595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial.
    Tanaka A; Kida K; Matsue Y; Imai T; Suwa S; Taguchi I; Hisauchi I; Teragawa H; Yazaki Y; Moroi M; Ohashi K; Nagatomo D; Kubota T; Ijichi T; Ikari Y; Yonezu K; Takahashi N; Toyoda S; Toshida T; Suzuki H; Minamino T; Nogi K; Shiina K; Horiuchi Y; Tanabe K; Hachinohe D; Kiuchi S; Kusunose K; Shimabukuro M; Node K
    Eur Heart J; 2024 Nov; 45(42):4482-4493. PubMed ID: 39215531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction.
    Shi YJ; Yang CG; Qiao WB; Liu YC; Liu SY; Dong GJ
    Eur J Pharmacol; 2023 Dec; 961():176170. PubMed ID: 37939991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
    Schauer A; Adams V; Augstein A; Jannasch A; Draskowski R; Kirchhoff V; Goto K; Mittag J; Galli R; Männel A; Barthel P; Linke A; Winzer EB
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.